COVID-19 prognosis in systemic lupus erythematosus compared with rheumatoid arthritis and spondyloarthritis: results from the CONTROL-19 Study by the Italian Society for Rheumatology.
COVID-19
autoimmune diseases
lupus erythematosus, systemic
Journal
Lupus science & medicine
ISSN: 2053-8790
Titre abrégé: Lupus Sci Med
Pays: England
ID NLM: 101633705
Informations de publication
Date de publication:
10 2023
10 2023
Historique:
received:
30
04
2023
accepted:
24
09
2023
medline:
23
10
2023
pubmed:
18
10
2023
entrez:
17
10
2023
Statut:
ppublish
Résumé
Data concerning SARS-CoV-2 in patients affected by SLE are contradicting.The aim of this study was to investigate disease-related differences in COVID-19 prognosis of patients affected by rheumatic diseases before vaccination; we tested the hypothesis that patients with SLE may have a different outcome compared with those with rheumatoid arthritis (RA) or spondyloarthritis (SPA). We analysed data from the national CONTROL-19 Database with a retrospective, observational design, including rheumatic patients affected by COVID-19. The principal outcome measure was hospitalisation with death or mechanical ventilation. Differences between SLE, RA and SPA were analysed by univariable and multivariable logistic regression models. We included 103 patients with SLE (88.2% female, mean age 48.9 years, 50.4% active disease), 524 patients with RA (74.4% female, mean age 60.6 years, 59.7% active disease) and 486 patients with SPA (58.1% female, mean age 53.2 years, 58% active disease).Outcome prevalence was not different between patients with SLE and those with RA (SLE 24.5%, RA 25.6%), while patients with SPA showed a more favourable outcome compared with those with SLE (SPA 15.9%); data from the multivariable analysis confirmed this result.In SLE, age >65 years (OR 17.3, CI 5.51 to 63.16, p<0.001), hypertension (OR 6.2, CI 2.37 to 17.04, p<0.001) and prednisone (PDN) use (OR 3.8, CI 1.43 to 11.39, p=0.01) were associated with severe outcomes, whereas hydroxychloroquine use was found to be protective (OR 0.3, CI 0.14 to 0.91, p=0.03). Our data suggest that patients with SLE and RA do not show a different COVID-19 outcome, while patients with SPA have a more favourable disease course compared with those with SLE. Risk of hospitalisation with ventilation or death was associated with age >65 years, hypertension and PDN use in patients with SLE.
Identifiants
pubmed: 37848262
pii: 10/2/e000945
doi: 10.1136/lupus-2023-000945
pmc: PMC10582885
pii:
doi:
Substances chimiques
Prednisone
VB0R961HZT
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Clin Exp Rheumatol. 2022 Nov;40(11):2038-2043
pubmed: 35260224
Lancet Rheumatol. 2020 Sep;2(9):e557-e564
pubmed: 32838309
Clin Exp Rheumatol. 2020 Jul-Aug;38(4):748-753
pubmed: 32723435
Ann Rheum Dis. 2020 Oct;79(10):1382-1383
pubmed: 32398281
Int J Rheum Dis. 2020 Aug;23(9):1255-1257
pubmed: 32841510
Lancet Rheumatol. 2020 Sep;2(9):e549-e556
pubmed: 32838307
Nature. 2020 Aug;584(7821):430-436
pubmed: 32640463
Ann Rheum Dis. 2022 Jul;81(7):970-978
pubmed: 35172961
Ann Rheum Dis. 2020 Jun;79(6):837-839
pubmed: 32332072
Lancet Rheumatol. 2020 Aug;2(8):e452-e454
pubmed: 32835249
Ann Rheum Dis. 2021 Feb;80(2):e25
pubmed: 32451344
Clin Immunol. 2021 Oct;231:108845
pubmed: 34478882
Autoimmun Rev. 2020 Jul;19(7):102575
pubmed: 32376395
Arthritis Res Ther. 2020 Dec 30;22(1):290
pubmed: 33380344
Clin Infect Dis. 2020 Jul 28;71(15):732-739
pubmed: 32150618
N Engl J Med. 2020 Apr 30;382(18):1708-1720
pubmed: 32109013
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Ann Rheum Dis. 2020 Oct;79(10):1386-1388
pubmed: 32381561
Clin Rheumatol. 2020 Jul;39(7):2055-2062
pubmed: 32277367
Lupus Sci Med. 2023 Feb;10(1):
pubmed: 36787921
Cell. 2020 Apr 16;181(2):281-292.e6
pubmed: 32155444
Ann Rheum Dis. 2021 Jun;80(6):e94
pubmed: 32586921
RMD Open. 2023 Mar;9(1):
pubmed: 36889799
Rheumatol Int. 2020 Oct;40(10):1593-1598
pubmed: 32794113
Proc Natl Acad Sci U S A. 2020 Jun 30;117(26):14857-14863
pubmed: 32527856
Ann Rheum Dis. 2020 Jul;79(7):851-858
pubmed: 32503854
Ann Rheum Dis. 2020 Sep;79(9):1156-1162
pubmed: 32457048
Lancet Rheumatol. 2020 May;2(5):e250-e253
pubmed: 32309814
J Clin Med. 2021 Aug 27;10(17):
pubmed: 34501290
Front Pharmacol. 2021 May 06;12:584940
pubmed: 34025393
Ann Rheum Dis. 2021 Apr;80(4):e54
pubmed: 32475831
Lupus. 2009 Nov;18(13):1169-75
pubmed: 19880563
Semin Arthritis Rheum. 2020 Oct;50(5):1150-1157
pubmed: 32927376
Lupus Sci Med. 2020 May;7(1):
pubmed: 32376774
Science. 1994 Jun 24;264(5167):1918-21
pubmed: 8009221
JAMA Intern Med. 2020 Jul 1;180(7):934-943
pubmed: 32167524
N Engl J Med. 2020 Apr 16;382(16):1564-1567
pubmed: 32182409
Arthritis Rheumatol. 2021 Mar;73(3):374-380
pubmed: 33146001
Transl Res. 2021 Jun;232:13-36
pubmed: 33352298
Ann Rheum Dis. 2021 May;80(5):e71
pubmed: 32669305
Lupus. 2021 Oct;30(12):1946-1954
pubmed: 34565208
RMD Open. 2021 Jan;7(1):
pubmed: 33510041